Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit: 2012-2025

Historic Gross Profit for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $134.4 million.

  • Ani Pharmaceuticals' Gross Profit rose 57.67% to $134.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year increase of 52.23%. This contributed to the annual value of $364.2 million for FY2024, which is 19.28% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Gross Profit stood at $134.4 million, which was down 1.71% from $136.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Gross Profit high stood at $136.8 million for Q2 2025, and its period low was -$8.8 million during Q1 2021.
  • Moreover, its 3-year median value for Gross Profit was $85.3 million (2024), whereas its average is $96.8 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 131.41% in 2021, then spiked by 443.84% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Gross Profit stood at $27.0 million in 2021, then skyrocketed by 114.22% to $57.9 million in 2022, then surged by 35.11% to $78.2 million in 2023, then spiked by 40.98% to $110.3 million in 2024, then surged by 57.67% to $134.4 million in 2025.
  • Its Gross Profit stands at $134.4 million for Q3 2025, versus $136.8 million for Q2 2025 and $124.1 million for Q1 2025.